

## Second-hand smoke surveillance and COVID-19: a missed opportunity

### INTRODUCTION

SARS-CoV-2 infection (COVID-19) causes severe respiratory illness and multiorgan inflammatory disease.<sup>1</sup> Smoking, cardiovascular disease (CVD), hypertension and chronic lung diseases are risk factors for COVID-19 severity.<sup>2-4</sup> Second-hand tobacco smoke (SHS) exposure is a known causal risk factor for CVD and chronic lung disease,<sup>5</sup> and may also be a risk factor for COVID-19 severity, either through its role in these underlying conditions, or through its inflammatory effect on upregulation of ACE-2 receptors, mediating COVID-19 cell entry.<sup>4</sup> However, a lack of SHS surveillance makes it difficult to quantify any potential relationship or to make evidence-informed recommendations about the effects of SHS exposure on COVID-19 incidence or severity. To learn more about whether SHS exposure was being assessed in COVID-19 studies, we contacted researchers who had published COVID-19-related work.

### METHODS

We contacted corresponding authors of peer-reviewed scientific articles published between February and April of 2020 identified by PubMed systematic searches using 'COVID OR Coronavirus AND Risk Factors' and similar terms. Abstracts were reviewed and papers included if they had data from patients with COVID-19 and risk factors. We emailed these authors, citing World Health Organization (WHO) and Centers for Disease Control (CDC) evidence for SHS exposure as a risk factor for worse COVID-19 outcomes, and asked authors whether they had data that would allow them to examine the hypothesis that exposure to SHS might be a risk factor for more severe disease or worse outcomes from COVID-19, both for children and also for adults with underlying conditions.

### RESULTS

Our searches identified 445 items, of which 328 papers (312 authors) met inclusion criteria and were emailed. Of these, 299 were deliverable and 66 authors responded (22%). Authors at government agencies (n=17) were two times as likely (41%;  $p<0.05$ ) to respond to emails. Most (92%) authors reported that they had not collected data on SHS exposure. Only three authors identified any SHS

exposures, and none had systematic SHS data. Many respondents acknowledged the potential significance of these omissions:

'Thanks for the interest...unfortunately I don't have...any data on SHS and COVID-19'.

'Thank you for reaching out. I cannot agree with you more...(we now have) included smoking as well as vaping as possible risk factors'.

'Your email makes me realise that there is still a long way to go before we reach the goal of minimising second-hand smoking'.

US CDC respondents referred our queries to the CDC Office of Smoking or Health, whose staff were familiar with the issue (and have validated measures available); however, these were not used in CDC's COVID-19 surveillance reporting form,<sup>6</sup> or by WHO or other national or regional public health agencies.

### CONCLUSION

None of the researchers who responded to our queries had data to assess SHS exposure as a risk factor for COVID-19 severity or outcomes. While public health and medical guidelines encourage clinicians to assess SHS exposure,<sup>7,8</sup> the early COVID-19 surveillance and registry efforts were established very quickly, reflecting the urgency of the pandemic's impact on healthcare systems worldwide. Nonetheless, in response to our queries, several authors acknowledged the missed opportunity to obtain data that might inform future public health interventions for COVID-19.

Some early reports have found substantial differences in smoker versus non-smoker COVID-19 mortality.<sup>9</sup> However, the most recent living rapid evidence review found former smokers at increased risk of hospitalisation, disease severity and mortality compared with never smokers.<sup>10,11</sup> For current smokers, hospitalisation and mortality associations were inconclusive, but the association with disease severity was likely significant.<sup>11</sup> Reporting and measurement of smoking status was highly variable across these studies: 30% (of more than 400 studies) reported current, former and never smoking status, only 8 studies reported use of alternative nicotine products, and none reported SHS exposure.<sup>11</sup>

Some public health agencies leading emergency responses and surveillance and researchers addressing COVID-19 risk factors may find systematic questions about smoking or SHS beyond the scope of rapid response surveillance. Multiple measures for any one risk factor are unlikely to be prioritised in pandemic responses; however,

tobacco control experts have proposed a simple, single item ('Are you exposed to smoke from cigarettes or other tobacco products?') for SHS exposure surveillance.<sup>12</sup>

Improved coordination between tobacco control leaders and public health leaders leading emergency responses and surveillance is needed to improve screening protocols and ask appropriate questions about COVID-19 and SHS exposure in future research and surveillance; unless we ask these questions, we will continue to miss opportunities to advance our understanding of the impact of smoke or vaping exposure on COVID-19, or other disease outcomes.

Jonathan D Klein <sup>1,2</sup> Elissa A Resnick,<sup>1</sup> Margaret E Chamberlin,<sup>3</sup> Elizabeth A Kress<sup>4</sup>

<sup>1</sup>Pediatrics, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA

<sup>2</sup>Julius B. Richmond Center of Excellence, American Academy of Pediatrics, Itasca, Illinois, USA

<sup>3</sup>American Institute of Biological Sciences, Reston, Virginia, USA

<sup>4</sup>Flight Attendant Medical Research Institute, Coral Gables, Florida, USA

**Correspondence to** Dr Jonathan D Klein, Pediatrics, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA; jonklein@uic.edu

**Contributors** All authors participated in the conception and design of the study. JDK and EAR wrote the manuscript and all authors participated in revising the manuscript and have given final approval of the manuscript.

**Funding** JDK's work is supported in part by grant #052303 from the Flight Attendant Medical Research Institute to the American Academy of Pediatrics Julius B Richmond Center of Excellence.

**Competing interests** No, there are no competing interests.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

This article is made freely available for personal use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Klein JD, Resnick EA, Chamberlin ME, *et al.* *Tob Control* 2023;**32**:265–266.

Received 4 February 2021

Accepted 18 May 2021

Published Online First 11 June 2021

*Tob Control* 2023;**32**:265–266.

doi:10.1136/tobaccocontrol-2021-056532

### ORCID iD

Jonathan D Klein <http://orcid.org/0000-0003-4185-1998>

## REFERENCES

- 1 World Health Organization. Coronavirus disease (COVID-19) pandemic [Available from. Available: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
- 2 World Health Organization. *World health organization statement: Tobacco use and COVID-19*, 2020.
- 3 Centers for Disease Control and Prevention. Coronavirus Disease 2019: People with Certain Medical Conditions 2020 [updated July 17, 2020. Available: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking>
- 4 Hoffmann M, Kleine-Weber H, Schroeder S, *et al*. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020;181:271–80.
- 5 Office on Smoking and Health. *Publications and reports of the surgeon General. The health consequences of involuntary exposure to tobacco smoke: a report of the surgeon General*. Atlanta (GA): Centers for Disease Control and Prevention (US), 2006.
- 6 Centers for Disease Control and Prevention. Human infection with 2019 novel coronavirus case report form, 2020. Available: <https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf>
- 7 Clinical practice guideline treating tobacco use dependence update panel liaisons and staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. public health service report. *Am J Prev Med* 2008;35:158–76.
- 8 Farber HJ, Walley SC, Groner JA, *et al*. Clinical practice policy to protect children from tobacco, nicotine, and tobacco smoke. *Pediatrics* 2015;136:1008–17.
- 9 Eastin C, Eastin T. Clinical characteristics of coronavirus disease 2019 in China: Guan W, Ni Z, HU Y, *et al*. *The Journal of Emergency Medicine* 2020;58:711–2.
- 10 Simons D, Shahab L, Brown J, *et al*. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). *Addiction* 2021;116:1319–68.
- 11 Simons D, Shahab L, Brown J, *et al*. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 11). *Qeios* 2021.
- 12 Klein JD, Chamberlin ME, Kress EA, *et al*. Asking the right questions about secondhand smoke. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco* 2019.